

JAN 18 2006

Atty Docket No. 016866-003810US

PTO FAX NO.: 1-571-273-8300

ATTENTION: Examiner Brandon J. Fetterolf

Group Art Unit 1642

OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Brandon J. Fetterolf

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following document in re Application of YIP et al., Application No. 10/088,970, filed July 19, 2002, for PROSTATE CANCER MARKER PROTEINS is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1642 (6 pp.).

Number of pages being transmitted, including this page: 7

Dated: January 18, 2006


Jo Ann Honcik Dallara for
Kenneth A. Weber, Reg. 31,677

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300
0860


60682204 v1

JAN 18 2006

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on January 18, 2006

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE –
EXAMINING GROUP 1642

TOWNSEND and TOWNSEND and CREW LLP

By: 
Jo Ann Honcik Dallara

PATENT
Attorney Docket No.: 016866-003810US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YIP et al.

Application No.: 10/088,970

Filed: July 19, 2002

For: PROSTATE CANCER MARKER
PROTEINS

Customer No.: 53671

Confirmation No. 6649

Examiner: Fetterolf, Brandon J

Technology Center/Art Unit: 1642

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1642

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed December 21, 2005, for the above-referenced application, please enter the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.